Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Anushka Mukherji

1 Small-Cap Biotech That Analysts Expect to Triple

Amid a surge in mental health disorders and growing demand for psychedelic drugs for therapeutic use, the global psychedelic drugs market is projected to hit $6.4 billion in 2034, exhibiting a steady compound annual growth rate (CAGR) of 12.2% from 2024 to 2034. One stock that’s well-positioned to benefit from this trend is small-cap biotech company Mind Medicine (MNMD), also known as MindMed.

In a recent milestone, the company announced its inclusion in the benchmark Russell 2000 Index (RUT) of small-cap stocks. This recognition not only underscores Mind Medicine’s commitment to advancing treatments for brain health disorders, but also brings the stock to a new audience of investors and portfolio managers.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.